Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.
Publication
, Conference
Friedlander, TW; Milowsky, MI; O'Donnell, PH; Petrylak, DP; Hoimes, CJ; Flaig, TW; Mar, N; Moon, HH; McKay, RR; Bilen, MA; Borchiellini, D ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Friedlander, T. W., Milowsky, M. I., O’Donnell, P. H., Petrylak, D. P., Hoimes, C. J., Flaig, T. W., … Rosenberg, J. E. (2023). Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Friedlander, Terence W., Matthew I. Milowsky, Peter H. O’Donnell, Daniel P. Petrylak, Christopher J. Hoimes, Thomas W. Flaig, Nataliya Mar, et al. “Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Friedlander TW, Milowsky MI, O’Donnell PH, Petrylak DP, Hoimes CJ, Flaig TW, et al. Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
Friedlander, Terence W., et al. “Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.
Friedlander TW, Milowsky MI, O’Donnell PH, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, McKay RR, Bilen MA, Borchiellini D, Iafolla M, Carret A-S, Yu Y, Guseva M, Kataria RS, Rosenberg JE. Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data. JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences